Vaccinex has completed two Phase 1 trials for VX15/2503 (one for advanced solid tumors, one for multiple sclerosis) and is in the middle of a Huntington's disease Phase 2 trial called SIGNAL for their VX15/2503 (monoclonal antibody that targets Semaphorin 4D (SEMA4D, CD100)). Here are their trials on clinicaltrials.gov. Vaccinex is pursuing both immuno-oncology and neurology applications. This SEMA4D antibody program seems to be their lead program.